Profile data is unavailable for this security.
About the company
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-β (THR-β) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Company’s clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.
- Revenue in USD (TTM)14.64m
- Net income in USD-510.45m
- Incorporated2000
- Employees376.00
- LocationMadrigal Pharmaceuticals Inc200 Barr Harbor Dr Ste 400WEST CONSHOHOCKEN 19428-2978United StatesUSA
- Phone+1 (404) 380-9263
- Fax+1 (302) 655-5049
- Websitehttps://www.madrigalpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apogee Therapeutics Inc | 0.00 | -118.49m | 3.42bn | 91.00 | -- | 4.28 | -- | -- | -2.25 | -2.25 | 0.00 | 13.65 | 0.00 | -- | -- | 0.00 | -25.44 | -- | -26.65 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -111.10 | -- | -- | -- |
| MoonLake Immunotherapeutics | 0.00 | -54.80m | 3.45bn | 50.00 | -- | 6.53 | -- | -- | -0.9043 | -0.9043 | 0.00 | 8.28 | 0.00 | -- | -- | 0.00 | -11.08 | -- | -11.49 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 27.95 | -- | -- | -- |
| Dyne Therapeutics Inc | 0.00 | -257.60m | 3.67bn | 152.00 | -- | 4.73 | -- | -- | -3.58 | -3.58 | 0.00 | 7.74 | 0.00 | -- | -- | 0.00 | -47.82 | -52.81 | -50.15 | -57.45 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.36 | -- | 40.32 | -- |
| TG Therapeutics Inc | 346.73m | 95.69m | 3.82bn | 300.00 | 41.08 | 21.49 | 39.82 | 11.01 | 0.6001 | 0.6001 | 2.29 | 1.15 | 1.11 | 0.4505 | 6.86 | 1,313,356.00 | 30.76 | -62.87 | 43.42 | -80.06 | 92.76 | -- | 27.60 | -405.03 | 2.83 | 8.21 | 0.3661 | -- | 8,290.02 | 333.86 | 106.39 | -- | -- | -- |
| Biohaven Ltd | 0.00 | -746.61m | 3.82bn | 239.00 | -- | 9.72 | -- | -- | -9.15 | -9.15 | 0.00 | 4.16 | 0.00 | -- | -- | 0.00 | -137.07 | -- | -176.64 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 28.43 | -- | -- | -- |
| Crinetics Pharmaceuticals Inc | 1.39m | -258.54m | 4.25bn | 290.00 | -- | 5.07 | -- | 3,071.40 | -3.77 | -3.77 | 0.0201 | 10.47 | 0.0023 | -- | 0.4157 | 4,775.86 | -41.16 | -42.53 | -44.29 | -45.36 | -- | -- | -18,257.91 | -5,446.39 | -- | -- | 0.00 | -- | -15.28 | 10.57 | -30.88 | -- | 34.65 | -- |
| Immunovant Inc | 0.00 | -272.55m | 4.28bn | 207.00 | -- | 7.85 | -- | -- | -1.92 | -1.92 | 0.00 | 3.73 | 0.00 | -- | -- | 0.00 | -57.93 | -- | -64.54 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -22.93 | -- | -- | -- |
| Denali Therapeutics Inc | 1.27m | -419.65m | 4.43bn | 364.00 | -- | 3.19 | -- | 3,492.69 | -2.85 | -2.85 | 0.0085 | 9.69 | 0.0009 | -- | -- | 2,847.19 | -29.89 | -14.98 | -31.50 | -17.71 | -- | -- | -33,121.86 | -104.50 | -- | -- | 0.00 | -- | 204.74 | 20.67 | 55.45 | -- | 30.70 | -- |
| Arcellx Inc | 144.75m | -53.89m | 4.66bn | 130.00 | -- | 9.53 | -- | 32.17 | -1.05 | -1.05 | 2.84 | 9.08 | 0.2132 | -- | -- | 1,113,423.00 | -7.94 | -38.82 | -9.68 | -45.41 | -- | -- | -37.23 | -339.38 | -- | -- | 0.038 | -- | -- | -- | 62.53 | -- | 113.86 | -- |
| Alkermes Plc | 1.51bn | 457.54m | 4.70bn | 2.10k | 10.68 | 3.69 | 9.23 | 3.12 | 2.67 | 1.69 | 8.78 | 7.74 | 0.6864 | 1.31 | 4.28 | 718,055.30 | 20.83 | 1.34 | 26.98 | 1.74 | 83.31 | 83.32 | 30.34 | 2.12 | 2.61 | -- | 0.184 | 0.00 | 49.61 | 8.74 | 1,665.99 | -- | -7.10 | -- |
| Madrigal Pharmaceuticals Inc | 14.64m | -510.45m | 5.07bn | 376.00 | -- | 5.91 | -- | 346.34 | -25.50 | -25.50 | 0.7351 | 39.50 | 0.0209 | -- | -- | 38,930.85 | -72.80 | -62.09 | -86.71 | -74.81 | 95.66 | -- | -3,487.13 | -- | 8.67 | -- | 0.1198 | -- | -- | -- | -26.50 | -- | 132.01 | -- |
| Krystal Biotech Inc | 166.23m | 105.94m | 5.29bn | 229.00 | 50.41 | 6.30 | 46.89 | 31.83 | 3.65 | 3.65 | 5.70 | 29.22 | 0.2076 | -- | -- | 725,908.30 | 13.23 | -11.50 | 14.07 | -12.01 | 93.07 | -- | 63.73 | -492.85 | 9.33 | -- | 0.00 | -- | -- | -- | 107.81 | -- | 39.49 | -- |
| Ultragenyx Pharmaceutical Inc | 481.30m | -585.12m | 5.41bn | 1.28k | -- | 12.52 | -- | 11.25 | -7.29 | -7.29 | 5.95 | 4.69 | 0.3286 | 1.81 | 5.45 | 377,196.70 | -39.94 | -33.35 | -48.51 | -38.30 | 87.15 | 93.13 | -121.57 | -154.71 | 3.39 | -- | 0.00 | -- | 19.52 | 53.18 | 14.25 | -- | 62.91 | -- |
| Blueprint Medicines Corp | 362.80m | -205.49m | 5.81bn | 638.00 | -- | 18.08 | -- | 16.01 | -3.42 | -3.42 | 5.85 | 5.07 | 0.3141 | 0.8694 | 5.88 | 553,887.00 | -17.79 | -29.92 | -21.66 | -34.06 | 96.19 | -- | -56.64 | -116.65 | 3.65 | -16.38 | 0.5471 | -- | 22.22 | 41.14 | 9.06 | -- | 4.85 | -- |
| Cytokinetics, Inc. | 3.13m | -545.28m | 6.33bn | 423.00 | -- | 58.22 | -- | 2,018.68 | -5.37 | -5.37 | 0.0309 | 0.9236 | 0.0027 | -- | 6.36 | 7,408.98 | -47.34 | -43.14 | -51.07 | -47.22 | -- | -- | -17,398.82 | -540.47 | -- | -12.85 | 0.8578 | -- | -92.04 | -24.89 | -35.30 | -- | 9.76 | -- |
Data as of Sep 20 2024. Currency figures normalised to Madrigal Pharmaceuticals Inc's reporting currency: US Dollar USD
71.66%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Janus Henderson Investors US LLCas of 30 Jun 2024 | 2.48m | 11.41% |
| Avoro Capital Advisor LLCas of 30 Jun 2024 | 2.06m | 9.47% |
| Baker Bros. Advisors LPas of 30 Jun 2024 | 1.97m | 9.09% |
| RTW Investments LPas of 30 Jun 2024 | 1.92m | 8.82% |
| Paulson & Co., Inc.as of 30 Jun 2024 | 1.85m | 8.52% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 1.76m | 8.10% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 1.27m | 5.83% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 30 Jun 2024 | 841.27k | 3.88% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 744.71k | 3.43% |
| Fidelity Management & Research Co. LLCas of 30 Jun 2024 | 673.98k | 3.10% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
